imaging drug delivery during CED, however, is akin to delivering a novel agent systemically without pharmacokinetics-something we would never tolerate. An essential element of observation then becomes the development and use of contrast reagents that can be quantified radiographically with high resolution. These researchers at the NIH 8, 9 and others, 10, 18 including us, 4, 13, [15] [16] [17] have used a number of different approaches for this purpose, but most recently small chelated Gd molecules alone or incorporated within liposomes 12 have been studied most extensively-in animal studies mostly, but in humans as well. 14 The study published here is one of a continuing set that elucidates the behavior of such tracers, and one in which it is claimed that a higher concentration of tracer results in a better match to the convection of the therapeutic and, further, that the volume of distribution (Vd) with the higher concentration of contrast reagent is greater than with the lower concentration. These data are derived by comparing the Vd of the Gd-diethylenetriamine pentaacetic acid (DTPA) tracer as measured using MR imaging with the Vd as measured by autoradiographic analyses in primates. The Vd on MR imaging here is obtained by simply using a threshold for segmentation as the MR imaging signal intensity value at least 10% above the mean signal from the surrounding noninfused anatomical region. This "threshold" type of approach has been used universally, especially for Gd-DTPA, except in our recent work. However, one does wonder if their conclusion is not a reflection of the actual convection of the contrast agents in the two cases, but instead simply the effect of the infusate with a lower concentration of contrast reagent having dropped below the threshold of detection beyond a certain distance (which corresponds to the time for which the agent has been infused). It is natural to suspect this, since the loss through the capillaries as well as other mechanisms will reduce the concentration over time and distance. It is for this and similar reasons that we favor the quantitative measurement of the concentration of the agent. It is true that it takes additional imaging to perform such measurements, but it would be interesting to see if various conclusions that have been drawn from the Vd measurements continue to hold when the more refined concentration measurements are made. If they do, then strictly quantifying these concentrations may not always be necessary, but an exhaustive evaluation of the parameters that affect this relationship will be needed. We believe, however, that the actual concentration of Gd-
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DTPA can be quantified by obtaining two spin density images, 3 instead of the customary one, at an appropriately set parameter (the flip angle). The ratio between the two signal intensities received, along with an assumption that the reciprocal of the T1 relaxation time varies linearly with the Gd-DTPA concentration, is sufficient to obtain the Gd-DTPA concentration. Even the slope of the linear variation (the relaxivity of Gd-DTPA in the tissue environment) can be calibrated by early observations and by knowing the amount of Gd-DTPA infused.
Several clinical trials using CED of large biological proteins as well as virus-sized particles are now underway for neurodegenerative disease as well as brain cancer. In the course of these studies, we must continue to verify that small-molecule tracers, such as Gd-DTPA, can be effective surrogates for the distribution of the variably sized therapeutic molecules or particles themselves. Diffusion and metabolic elimination, of course, add further measures of complexity to the picture of surrogate tracers, but knowing where the fluid carries the particles during the convective phase alone will be a valuable addition to understanding how CED behaves in the complex interstitial environment that includes white matter pathways, which can expand under infusion-induced edema, and blood vessels, which offer perivascular pathways for fluid as well as molecular transport. Backflow along the outer walls of the catheter are also significant paths for the fluid to take early in the infusion. Device designs to ameliorate this effect remain important and needed advances. 19 The use of tracers in studies utilizing CED are to be encouraged because many of the drugs delivered to the brain by CED are used in such low concentrations that they cannot be imaged directly. These studies will be most informative, however, if we all adhere to a rigid and reproducible methodology that allows us to precisely quantify the distribution of the tracer in absolute amounts. Further work should focus on confirming the significant differences, if any, between the distribution of small and large molecules at different concentrations in different disease states in humans, testing the safety of different tracers in humans and obtaining approval from the FDA for new tracers, and developing technical adjuncts that help us better deliver a broad range of therapeutics to precise targets within the brain. With such an approach, we may one day make that critical shift from dogma to data.
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